NZNew Zealand
Unapproved peptides in New Zealand rise as customs parcels more than double and needle demand jumps
Customs detained 840 peptide parcels to September, more than double all of 2025, while needle demand grew about fivefold and drug checkers saw 67 samples. Medsafe says no local laboratory can test these products to medicine standards.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itCustoms seizures, needle demand, drug checking samples and Medsafe reports all show rising use of unapproved peptides in New Zealand, where no local lab can test them to medicine standards.
New Zealand's health agencies are counting a sharp rise in self injected peptides bought outside the law. Figures gathered by The Spinoff on 20 November show customs detaining more parcels of unapproved peptides, needle demand climbing and more samples reaching drug checkers, two weeks after Medsafe issued a fresh warning on 4 November. Some of the products are research labelled compounds that are approved nowhere, such as retatrutide. Others are copies of medicines that are legal on prescription. The numbers come from several agencies and do not add up to a single measure of use.
What the border and needle numbers show
New Zealand Customs detained 840 parcels of peptides in 2026 up to September, the Spinoff reported, against 370 in the whole of 2025. A customs spokesperson said officers work with Medsafe to pick out risky mail and refer items that need a prescription, and that unlabelled or unprescribed contents are destroyed. Demand for insulin needles through the national needle exchange programme rose about fivefold between 2025 and 2026, according to figures first reported by The Post. Health New Zealand has since supplied 2,300 free injecting kits for peptide users to pharmacies through the programme. Before the kits went out, pharmacies had reported running short of the diabetic syringes these users rely on.
Deborah Woodley of Health New Zealand said the uptake "reflects the significant demand for equipment" and that the kits are not an "endorsement of unapproved peptide use". The needle exchange serving much of the upper and central North Island told the Spinoff that 40 percent of its clients now ask for help with peptides. Online interest follows the same line. Searches for peptides on Google in New Zealand began rising in mid 2025, around the time the country approved its first weight loss peptides, and reached their high point in August 2026. The Post reported that more than 25 local peptide websites have been shut down so far, and a Medsafe spokesperson said the agency is still contacting sites based in the country to tell them such sales break the law.
Medsafe warnings and reports of harm
Medsafe has now warned twice this year. A consumer advisory on 21 May named a dozen unapproved peptides and selective androgen receptor modulators, among them BPC 157, TB 500 and melanotan II, and said the list was not complete. The November safety alert of 4 November went further. It said the national pharmacovigilance database held 10 reports of adverse reactions to these products as of 21 October, five of which involved a hospital stay or came from a hospital. Most described stomach and gut symptoms, and half mentioned possible effects on the heart. Most of the reports involved people who believed they were taking retatrutide, a Lilly compound still in clinical trials.
Medsafe said it is not aware of any laboratory in New Zealand that can test unapproved peptides to the standard required for medicines.
The agency also addressed a common sales pitch. A "research only" label has no legal effect, Medsafe says, and it does not permit sale, supply or human use. Medsafe said it is not aware of any laboratory in New Zealand that can test unapproved peptides to the standard required for medicines. That leaves buyers with no reliable way to check what is in a vial. The Spinoff also pointed to Australian testing in which 30 percent of black market retatrutide samples held more of the compound than the label stated. Medsafe tells anyone who feels unwell after using such products to seek urgent care and to tell clinicians what they took, and asks for side effects to be reported to its database.
| Measure | Figure | Source |
|---|---|---|
| Peptide parcels detained by customs, 2026 to September | 840 | New Zealand Customs via The Spinoff |
| Peptide parcels detained by customs, 2025 | 370 | New Zealand Customs via The Spinoff |
| Rise in insulin needle demand, 2025 to 2026 | About five times | The Post |
| Free peptide injecting kits sent to pharmacies | 2,300 | Health New Zealand |
| Adverse reaction reports to 21 October 2026 | 10 | Medsafe alert of 4 November |
| Peptide samples brought to drug checkers in 2026 | 67 | NZ Drug Foundation |
| Local peptide websites shut down | More than 25 | The Post |
Drug checking and the law
The New Zealand Drug Foundation sees the trend in its clinics. Executive director Sarah Helm said the clinic logged a single sample in 2023 and six in 2024, then 11 in 2025 and 67 by November this year. It also fielded close to 100 public questions about peptides, most of them during the last year and a half. "In a handful of samples we've found fillers such as flour, which could cause problems if injected," she said. Yet the foundation cannot say whether a sample holds a peptide at all, which one it is or how much is present, and it cannot screen for heavy metals, bacteria, endotoxins or mould. Helm called for significant investment to build robust testing that approved laboratories could use, so that public health teams can track what is circulating.
The legal position is plain on paper. Buying unapproved products such as retatrutide is illegal, and so is importing or holding a prescription medicine such as Wegovy without a prescription. A 23 year old Palmerston North man has been charged with possessing retatrutide and the prescription only steroid testosterone enanthate. The general penalties in the Medicines Act 1981 are modest, a fine of up to 500 dollars or three months in prison, and promoting unapproved medicines is also an offence. Readers in other markets will recognise the pattern. Health Canada found contamination in seized peptide vials. Britain, for its part, has moved against unlicensed retatrutide promoted on social media.
Why the legal route loses out on price
Price is part of the story. Wegovy is approved in New Zealand but is not publicly funded, so patients pay the full retail price, which the Spinoff put at between 370 and 475 New Zealand dollars depending on the strength. One user told RNZ that this cost led them to an unapproved weight loss compound instead, a choice that carries all the risks Medsafe lists. The gap mirrors what Peptide Global has seen in Korea, where high prices for approved GLP 1 medicines push some buyers toward cheaper channels with no quality control. In New Zealand the scale of the illicit market is unknown, as customs and drug checkers only see the share they catch or are shown.
Across the Tasman the problem is already showing up in hospitals. New South Wales emergency departments recorded 1,180 presentations linked to peptides over 15 months, with monthly cases climbing from five in July 2025 to 217 by September 2026, the Spinoff reported. New Zealand has no comparable count yet. What to watch next is whether Medsafe adds more compounds to its warnings, whether customs figures for the last quarter keep climbing, and whether the government funds the laboratory testing that Helm and Medsafe both say is missing. A decision on funding for approved weight loss medicines would also change the incentive to buy outside the system.
Conclusion
Use of unapproved peptides in New Zealand appears to be rising on every measure officials can see: customs parcels, needle demand, drug checking samples and reports to Medsafe. The regulator says no local laboratory can verify these products, and the law treats buying them as illegal. How large the market is, and what it costs in harm, remains unknown.
Why it matters in New Zealand
Wegovy is approved but unfunded in New Zealand, and research labelled peptides such as retatrutide arrive by mail. Health New Zealand now hands out injecting kits while Medsafe warns that buying these products is illegal and unsafe.
What to watch
Customs figures for the last quarter of 2026, any new Medsafe warnings, and whether the government funds laboratory testing for peptides or public cover for approved weight loss drugs.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.